Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A 15-DNA Repair Gene Prognostic Signature for Immunotherapy in Gastric Cancer

Binbin Yuan
ORCID logo ,
Chengfei Jiang
,
Lingyan Chen
,
Jinlong Cui
,
Min Chen
,
Shu Zhang
,
Yimeng Cai
,
Jian-Hua Mao
ORCID logo ,
Xiaoping Zou
* ,
Bo Hang
* ,
Pin Wang
* ORCID logo
Version 1 : Received: 19 October 2021 / Approved: 20 October 2021 / Online: 20 October 2021 (22:47:19 CEST)

How to cite: Yuan, B.; Jiang, C.; Chen, L.; Cui, J.; Chen, M.; Zhang, S.; Cai, Y.; Mao, J.; Zou, X.; Hang, B.; Wang, P. A 15-DNA Repair Gene Prognostic Signature for Immunotherapy in Gastric Cancer. Preprints 2021, 2021100297. https://doi.org/10.20944/preprints202110.0297.v1 Yuan, B.; Jiang, C.; Chen, L.; Cui, J.; Chen, M.; Zhang, S.; Cai, Y.; Mao, J.; Zou, X.; Hang, B.; Wang, P. A 15-DNA Repair Gene Prognostic Signature for Immunotherapy in Gastric Cancer. Preprints 2021, 2021100297. https://doi.org/10.20944/preprints202110.0297.v1

Abstract

Gastric cancer is a heterogeneous group of diseases with only a fraction of patients responds to immunotherapy. The relationships between tumor DNA damage response, the immune system and immunotherapy have recently attracted attention. Accumulating evidence indicate that DNA repair landscape is a significant factor in driving response to immune checkpoint blockade (ICB) therapy. In this study, to explore new prognostic and predictive biomarkers for gastric cancer patients who are sensitive and responsible to immunotherapy, we developed a novel 15-DNA repair gene signature (DRGS) and its related scoring system and evaluated the efficiency of DRGS in discriminating different molecular and immune characteristics and therapeutic outcomes of gastric adenocarcinoma. The results showed that DRGS high score patients showed significantly better therapeutic outcomes compared to DRGS low score patients (P < 0.001). Integrated analysis of multi-omics data demonstrated that the patients with high DRGS score were characteristic of high levels of anti-tumor lymphocytes infiltration, tumor mutation burden (TMB) and PD-L1 expression, and these patients exhibited a longer overall survival and may benefit more from ICB therapy, as compared to the low-score patients. Therefore, the DRGS and its scoring system may have implications in tailoring immunotherapy in gastric cancers.

Keywords

gastric cancer; immunotherapy; immune checkpoint blockade (ICB); immune checkpoint inhibitors (ICI),; DNA repair gene signature (DRGS); prognostic biomarker; score system

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.